Stanford’s Virtual Biotech uses thousands of AI agents to shrink drug discovery timelines, boost precision and cut costs, with open-source, human-verified outputs.
Stanford Virtual Biotech: AI Agents Speed Drug Discovery to Weeks Read More »
How AI and deep learning are accelerating discovery of novel compounds for Alzheimer’s, shortening timelines and advancing candidates toward preclinical testing.
How AI Is Speeding Up Drug Discovery for Alzheimer’s: A Practical Look Read More »
Major pharma firms are building in-house AI and automated labs. Roche, Novo Nordisk and Eli Lilly shift to dry-wet closed loop workflows to speed R&D and lift success rates.
AI Drug Discovery: Pharma Giants Double Down on Innovation Read More »
New AI platforms are shortening drug discovery timelines and shifting R&D priorities. What biotech and pharma leaders need to know now.
AI’s Immediate Impact on Drug Discovery: A Focused Update for Biotech Leaders Read More »
ByteDance’s Anew Labs raised $290M at a $1.5B valuation to accelerate AI-driven drug discovery with models Protenix and PXDesign. Series A led by HSG and others.
ByteDance’s Anew Labs Raises $290M at $1.5B Valuation to Scale AI Drug Discovery Read More »
72% of US pharma firms are scaling AI in R&D, yet only 24% expect large gains in drug success. A concise look at adoption, limits, and the human factor.
US Pharma’s AI Paradox: Widespread Adoption, Measured Expectations in Drug Discovery Read More »
AdaptiveFlow from St. Jude cuts virtual screening times to hours with 1,000-fold cost savings, open-source tools, and cloud-scale AI for faster therapeutic development.
AdaptiveFlow and the New Era of AI-Driven Drug Discovery Read More »
A concise update on how AI is accelerating drug discovery, from structure prediction to trial optimization, with industry examples and next steps.
How AI Is Reshaping Drug Discovery: Speed, Precision, and What Comes Next Read More »
Concise update on how AI speeds target identification, lead design, virtual screening and clinical trials, and what this means for precision medicine and pharma R&D.
How AI Is Reshaping Drug Discovery: Speed, Precision, and Risk Reduction Read More »
How AI and tech capital are shifting drug discovery to a fail-fast model, de-risking early R&D while creating investor tensions and strategic tradeoffs.
AI and the ‘Fail-Fast’ Revolution in Drug Discovery Read More »
